Omeros Competitors and Similar CompaniesClear all
Omeros's competitors and similar companies include Tanvex BioPharma, BeyondSpring, Catalyst Pharmaceuticals, Akorn and ACADIA Pharmaceuticals.
 Omeros Omeros Corporation is a biopharmaceutical company developing products focused on inflammation and central nervous system disorders as well as immune-related diseases, including cancers. |  Tanvex BioPharma Tanvex BioPharma (formerly known as Ruenvex Biotech) is a company that manufactures and develops biosimilar and biologic products and drugs. |  BeyondSpring BeyondSpring (also known as Spring Pharmaceuticals) is a biopharmaceutical company focused on oncology therapies. |  Catalyst Pharmaceuticals Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases. |  Akorn Akorn is a niche pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals as well as animal and consumer health products. |  ACADIA Pharmaceuticals ACADIA Pharmaceuticals (formerly Receptor Technologies) is a biopharmaceutical company developing medicines that address medical needs in related central nervous system (CNS) disorders. | |
Founding Date | Founding Date 1994 | Founding Date 2013 | Founding Date 2010 | Founding Date 2002 | Founding Date 1948 | Founding Date 1993 |
Type | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public |
Tags | ||||||
Locations | Locations Seattle, US HQ | Locations Taipei, TW HQ New Taipei, TW Irvine, US San Diego, US San Diego, US | Locations Florham Park, US HQ | Locations Coral Gables, US HQ | Locations Lake Forest, US HQ Gurugram, IN Jawalpur, IN Jersey, JE Hettlingen, CH Amityville, US Ann Arbor, US see more | Locations San Diego, US HQ Princeton, US |
Employees | Employees 1968% decrease | Employees 13827% decrease | Employees 4014% increase | Employees 7649% increase | Employees 2,2272% increase | Employees 513 |
Valuation ($) | Valuation ($) 248.6 m | Valuation ($) N/A | Valuation ($) 89.4 m | Valuation ($) 2.6 b | Valuation ($) 12 m | Valuation ($) 2.4 b |
Financial | ||||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) NT$401m (FY, 2025) | Revenue (est.) N/A | Revenue (est.) $589m (FY, 2025) | Revenue (est.) $682.4m (FY, 2019) | Revenue (est.) $1.1b (FY, 2025) |
Cost of goods | Cost of goods N/A | Cost of goods NT$466.3m (FY, 2025) | Cost of goods N/A | Cost of goods $87.3m (FY, 2025) | Cost of goods $429.7m (FY, 2019) | Cost of goods $89m (FY, 2025) |
Gross profit | Gross profit N/A | Gross profit (NT$10.6m) (FY, 2025) | Gross profit N/A | Gross profit $501.7m (FY, 2025) | Gross profit $252.7m (FY, 2019) | Gross profit $982.5m (FY, 2025) |
Net income | Net income ($3.4m) (FY, 2025) | Net income (NT$1.5b) (FY, 2025) | Net income ($16.7m) (FY, 2024) | Net income $214.3m (FY, 2025) | Net income ($226.8m) (FY, 2019) | Net income $391m (FY, 2025) |
Operating ⚠ | ||||||
Patents (US) | Patents (US) 80 (FY, 2021) | Patents (US) N/A | Patents (US) 20 (Mar, 2020) | Patents (US) N/A | Patents (US) N/A | Patents (US) 47 (FY, 2021) |
Phase I Trials Products | Phase I Trials Products 3 (FY, 2021) | Phase I Trials Products N/A | Phase I Trials Products 2 (FY, 2019) | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products 1 (FY, 2021) |
Phase II Trials Products | Phase II Trials Products 2 (FY, 2021) | Phase II Trials Products N/A | Phase II Trials Products 1 (FY, 2017) | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products 1 (FY, 2021) |
Phase III Trials Products | Phase III Trials Products 2 (FY, 2021) | Phase III Trials Products N/A | Phase III Trials Products 3 (FY, 2019) | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products 3 (FY, 2021) |
Products Marketed | Products Marketed 1 (FY, 2021) | Products Marketed N/A | Products Marketed N/A | Products Marketed N/A | Products Marketed N/A | Products Marketed 1 (FY, 2021) |
Funding | ||||||
Total funding raised | Total funding raised $ 354.8m | Total funding raised $ 346.9m | Total funding raised $ 36.1m | Total funding raised N/A | Total funding raised N/A | Total funding raised $ 770.8m |
For sources of this data, please see the company profile
View Company Profiles
Tanvex BioPharma
HQ
Taipei, TW
Employees
138↓ 27% decrease
Tanvex BioPharma (formerly known as Ruenvex Biotech) is a company that manufactures and develops biosimilar and biologic products and drugs.
View companyBeyondSpring
HQ
Florham Park, US
Employees
40↑ 14% increase
BeyondSpring (also known as Spring Pharmaceuticals) is a biopharmaceutical company focused on oncology therapies.
View companyCatalyst Pharmaceuticals
HQ
Coral Gables, US
Employees
76↑ 49% increase
Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases.
View companyAkorn
HQ
Lake Forest, US
Employees
2,227↑ 2% increase
Akorn is a niche pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals as well as animal and consumer health products.
View company